Ashland Inc. Finalizes Sale of Nutraceuticals Division
Ashland Inc. (NYSE: ASH) has made a significant shift in its business strategy by completing the sale of its nutraceuticals division to an affiliate of Turnspire Capital Partners. This change took effect on August 30, 2024, marking a new beginning for both organizations. The agreement includes key elements of the nutrition market, such as custom formulation and contract manufacturing, with production facilities situated in the United States and Mexico.
Insights from Leadership on the Sale
Guillermo Novo, Ashland's chair and CEO, shared his appreciation for the employees' steadfast dedication over the years during discussions about the sale. He emphasized the strong portfolio of proprietary ingredients and the extensive manufacturing capabilities that the nutraceuticals division has built. Novo also extended his best wishes to Pharmachem Innovations, the new home for the nutraceuticals business, which is now part of Turnspire's broad network of companies.
Turnspire's Vision for Future Growth
Ilya Koffman, managing partner at Turnspire, acknowledged the cooperative efforts of Ashland's team in ensuring a successful transaction for everyone involved. He expressed enthusiasm about collaborating with the talented management and workforce at Pharmachem Innovations to elevate the business's position as a leader in the expanding nutraceutical sector.
Support Team Involved in the Transaction
Citi acted as the financial advisor throughout this transaction, while Cravath, Swaine & Moore LLP provided legal counsel to Ashland. The expertise of these firms was instrumental in facilitating a smooth process and achieving a successful outcome.
About Ashland Inc.
Ashland Inc. (NYSE: ASH) is recognized as a global leader in additive and specialty ingredient solutions. Committed to environmental, social, and governance (ESG) principles, Ashland serves a wide array of industries, including energy, food, beverage, personal care, pharmaceuticals, and construction. The company takes pride in its dedicated team of around 3,800 innovative professionals who are passionate about delivering effective solutions to complex challenges across more than 100 countries.
Contact Information
If you have any questions, please contact:
Investor Relations: William Whitaker
Phone: +1 (614) 790-2095
Email: wcwhitaker@ashland.com
Media Relations: Carolmarie C. Brown
Phone: +1 (302) 995-3158
Email: ccbrown@ashland.com
Frequently Asked Questions
What led Ashland to sell its nutraceuticals division?
Ashland is refocusing on its core business strategies and believes that selling the nutraceuticals division to Turnspire will be advantageous for both companies.
What will happen to the employees from the nutraceuticals division?
The employees will transition to Pharmachem Innovations, which is now part of the Turnspire family, allowing them to continue their careers in the nutraceuticals industry.
What advantages does this sale offer Ashland?
This sale enables Ashland to allocate its resources toward other business areas while allowing the nutraceuticals division to thrive under dedicated management at Turnspire.
Who provided advisory services to Ashland during the sale?
Citi served as the financial advisor, and Cravath, Swaine & Moore LLP acted as the legal advisor for Ashland during this transaction.
Where can I find more information about Ashland Inc.?
For further details about Ashland, visit their official website at ashland.com.
